Devices and methods for enrichment and alteration of circulating tumor cells and other particles

• US 20070026418A1
• Filed: 12/29/2005
• Published: 02/01/2007
• Est. Priority Date: 07/29/2005
• Status: Abandoned Application

• Current Assignee: GlobalFoundries, Inc., Gpb Scientific, LLC, Mehmet Toner
• Original Assignee: Mehmet Toner
• Inventors: Toner, Mehmet, Fuchs, Martin, Huang, Yi-Shuian, Wang, Ying-Xin, Huang, Lotien, Krueger, Neil
• Application Number:
  US11/324,041
• Publication Number:
  US 20070026418A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: B01L 2200/0647 Handling flowable solids, e.g. microscopic beads, cells, particles
• CPC Class Codes: B01L 2300/0636 Integrated biosensor, microarrays
• CPC Class Codes: B01L 2300/0816 Cards, e.g. flat sample carriers usually with flow in two horizontal directions
• CPC Class Codes: B01L 2300/0864 comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
• CPC Class Codes: B01L 2400/0409 centrifugal forces
• CPC Class Codes: B01L 2400/086 using baffles or other fixed flow obstructions
• CPC Class Codes: B01L 3/502746 characterised by the means for controlling flow resistance, e.g. flow controllers, baffles B01L3/502738 takes precedence
• CPC Class Codes: B01L 3/502753 characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation separation in general B01D; microapparatus for analysis using electrophoresis G01N27/44791; sample preparation G01N1/28
• CPC Class Codes: B01L 3/502761 specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules investigating characteristics of particles G01N15/00
• CPC Class Codes: B82Y 10/00 Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5005 involving human or animal cells immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025
• CPC Class Codes: G01N 33/54366 Apparatus specially adapted for solid-phase testing
• CPC Class Codes: G01N 33/57492 involving compounds localized on the membrane of tumor or cancer cells

Abstract

The invention features devices and methods for detecting, enriching, and analyzing circulating tumor cells and other particles. The invention further features methods of diagnosing a condition, e.g., cancer, in a subject by analyzing a cellular sample from the subject.

Claims

1. A device for processing a cellular sample, said device comprising a channel comprising an array of obstacles forming a network of gaps, wherein fluid flows through said gaps such that said fluid is divided unequally into a major flux and a minor flux, and wherein said array is configured to direct epithelial cells in a direction not parallel to the average direction of flow in said array.

2. The device of claim 1, wherein said device further comprises two inlets.

3. The device of claim 1, wherein said device further comprises two outlets.

4. The device of claim 1, further comprising a second device of claim 1, wherein said devices are fluidically coupled.

5. The device of claim 3, wherein said gaps are sized to direct epithelial cells to one of said outlets.

6. The device of claim 2, wherein said gaps are sized to direct epithelial cells from the fluid flowing into one said inlet to the fluid flowing into another said inlet.

7. The device of claim 1, wherein said obstacles comprise a polymer, silicon, glass, or fused silica.

9. A method of producing an enriched sample of epithelial cells, said method comprising introducing a cellular sample into the device of claim 1, wherein, as said cellular sample flows through said device, epithelial cells present in said cellular sample are directed in a direction not parallel to the average flow direction of said cellular sample and another component of said cellular sample is directed along the average flow direction, thereby producing a sample enriched in epithelial cells relative to said other component.

10. The method of claim 9, wherein said other component comprises red blood cells, platelets, leukocytes, or endothelial cells.

11. The method of claim 9, wherein said epithelial cells range from 8 μ

m to 30 μ

m in diameter.

12. The method of claim 9, wherein said cells are capable of undergoing DNA analysis, RNA analysis, protein analysis, or metabolome analysis.

13. The method of claim 12, wherein said cells are analyzed using in-cell PCR.

14. The method of claim 12, wherein said cells are analyzed by determining the level of cytokeratin mRNA present.

15. The method of claim 9, wherein said epithelial cells are cancer cells.

16. The method of claim 15, wherein said cancer cells are cancer stem cells.

17. The method of claim 9, wherein the volume of said enriched sample is substantially smaller than the volume of said cellular sample, resulting in concentration of said epithelial cells.

18. The method of claim 9, wherein a lysis buffer is co-introduced into said device, and wherein said enriched sample comprises components of epithelial cells.

19. The method of claim 9, wherein an exchange buffer is co-introduced into said device, and wherein said enriched sample comprises exchange buffer.

20. The method of claim 9, further comprising contacting said enriched sample with a labeling reagent that preferentially labels epithelial cells.

21. The method of claim 9, further comprising quantifying the number of cells in said enriched sample.

22. The method of claim 21, wherein said device determines the number of cells of cell volume greater than 500 fL in said enriched sample.

23. The method of claim 21, wherein said device determines the number of cells of diameter greater than 14 μ

m in said enriched sample.

24. The method of claim 9, wherein the shear stress on each of said cells inside said device is below 10 dynes per square centimeter at all times.

25. The method of claim 9, wherein said cellular sample is contacted with a labeling reagent that preferentially labels epithelial cells, wherein said labeling reagent is first combined with said cellular sample either prior to introduction of said cellular sample to said device or following introduction of said cellular sample to said device.

26. The method of claim 25, wherein said labeling reagent is a particulate labeling reagent.

27. The method of claim 25, said method further comprising quantifying said labeled cells.

28. The method of claim 27, wherein said labeling reagent comprises quantum dots, and said labeled cells are analyzed using 2-photon excitation.

29. The method of claim 28, said method further comprising making a bulk measurement of said enriched sample.

30. The method of claim 25, wherein labeling reagent bound to said cells is separated from labeling reagent that remains unbound to said cells.

31. The method of claim 25, wherein said labeling reagent is co-introduced into said device, resulting in labeling of said cells within said device.

32. The method of claim 25, wherein said labeling reagent comprises a quantum dot, an antibody, a phage, an aptamer, a fluorophore, an enzyme, or a bead.

33. The method of claim 32, wherein said bead comprises an affinity reagent.

34. The method of claim 32, wherein said bead comprises polystyrene.

35. The method of claim 32, wherein said bead is neutrally buoyant.

36. The method of claim 32, wherein said bead comprises an antibody.

37. The method of claim 25, wherein said labeling reagent increases the size of said cells.

38. The method of claim 37, wherein said size increases by at least 10%.

39. The method of claim 37, wherein said size increases by at least 100%.

40. The method of claim 37, wherein said size increases by at least 1000%.

41. A method of quantifying epithelial cells, said method comprising the steps of:

a. providing a cellular sample;

b. introducing said cellular sample into the device of claim 1 to produce a sample enriched in epithelial cells; and

c. quantifying said epithelial cells.

42. A diagnostic method comprising the steps of:

a. introducing a cellular sample from a patient into the device of claim 1 to produce a sample enriched in cells larger than normal blood cells; and

b. determining the number of cells larger than normal blood cells present in said sample to determine a disease state.

43. A diagnostic method comprising the steps of:

a. introducing a cellular sample from a patient into the device of claim 1 to produce a sample enriched in cells larger than normal blood cells; and

b. performing DNA analysis, RNA analysis, proteome analysis, or metabolome analysis on said enriched sample in order to determine a disease state.

44. The method of claim 43, wherein said DNA analysis comprises determining the presence and identity, or the absence, of one or more mutations in the epidermal growth factor receptor gene.

45. The method of claim 44, wherein said DNA analysis comprises the steps of:

i. isolating genomic DNA from said enriched sample; and

ii. amplifying one or more of exons 18, 19, 20, and 21 of said epidermal growth factor receptor gene.

46. The method of claim 45, further comprising the steps of:

iii. amplifying subregions of said amplification products corresponding to known epidermal growth factor receptor mutations, resulting in further amplification products;

iv. sequencing said further amplification products; and

v. comparing the resulting sequences to the wild-type sequence of said epidermal growth factor receptor gene and a list of known mutations of said epidermal growth factor receptor gene.

47. The method of claim 42 or 43, wherein said cells larger than normal blood cells comprise epithelial cells.

48. The method of claim 42 or 43, wherein said disease state comprises cancer.

8. A device for processing a cellular sample, said device comprising:

a. a channel comprising an array of obstacles forming a network of gaps, wherein fluid flows through said gaps such that said fluid is divided unequally into a major flux and a minor flux so that the average direction of movement of cells larger than a critical size is not parallel to the average direction of fluidic flow;

b. an outlet disposed to collect cells larger than normal blood cells; and

c. a cell detector that counts cells.

49. The device of claim 8, wherein said cells larger than normal blood cells comprise epithelial cells.

50. A device for processing a cellular sample, said device comprising a channel comprising a ceiling positioned over an array of obstacles that form a network of gaps, wherein said device is configured to allow cells having a diameter of less than or equal to a critical size to flow through said network of gaps, and to capture cells having a diameter of greater than said critical size between said ceiling and said obstacles.

51. The device of claim 50, wherein said critical size is between 5 and 20 microns.

52. The device of claim 50, wherein said critical size is 12 microns.

53. The device of claim 50, wherein said critical size is 14 microns.

54. The device of claim 50, wherein said cells having a diameter greater than said critical size comprise one or more rare cells.

55. The device of claim 54, wherein said rare cells comprise one or more epithelial cells, cancer cells, bone marrow cells, fetal cells, progenitor cells, stem cells, foam cells, mesenchymal cells, immune system cells, endothelial cells, endometrial cells, connective tissue cells, trophoblasts, bacteria, fungi, or pathogens.

56. The device of claim 50, wherein said ceiling is transparent.

57. A method of processing cells having a diameter of greater than a critical size in a cellular sample, said method comprising introducing said cellular sample into a device comprising a channel comprising a ceiling positioned over an array of obstacles that form a network of gaps, wherein said device is configured to allow cells having a diameter of less than or equal to said critical size to flow through said network of gaps, and to capture cells having a diameter of greater than said critical size between said ceiling and said obstacles.

58. The method of claim 57, further comprising detecting the presence or absence of said cells having a diameter of greater than said critical size between said ceiling and said obstacles.

59. The method of claim 58, wherein said ceiling is transparent, and wherein said detecting comprises using a microscope.

60. The method of claim 57, further comprising introducing a buffer, a lysis reagent, a nucleic acid amplification reagent, an osmolarity regulating reagent, a labeling reagent, a preservative, or a fixing reagent into said device subsequent to introducing said cellular sample.

61. The method of claim 60, wherein said osmolarity regulating reagent comprises a hypertonic solution.

62. The method of claim 61, wherein said hypertonic solution causes said cells having a diameter of greater than said critical size between said ceiling and said obstacles to be released.